News Jaguar Health, Inc.

Equities

JAGX

US47010C8881

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 14/03/2026 am IST			5-day change	1st Jan Change
0.5030 ^USD	-7.88%		-14.82%	-45.98%

18/02	Jaguar Health to Pay Special Stock Dividend	MT
16/01	Jaguar Health Inc - Co & unit entered license agreement with Woodward Specialty LLC - SEC filing	RE

All News

18/02	Jaguar Health to Pay Special Stock Dividend	MT
16/01	Jaguar Health Inc - Co & unit entered license agreement with Woodward Specialty LLC - SEC filing	RE
15/01	Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts	AQ
12/01	Jaguar Health : Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million	PU
06/01	Jaguar Health, Inc. announced that it has received $0.35 million in funding	CI
11/12	FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs	AQ
11/12	Jaguar Health : Corporate Presentation – December 10, 2025 (4f076c)	PU
10/12	Jaguar Health : FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs	PU
09/12	Jaguar Health : Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders	PU
24/11	Jaguar Health, Inc. announced that it has received $10.81 million in funding	CI
21/11	Jaguar Health : Corporate Presentation – November 17, 2025 (ca884a)	PU
21/11	Jaguar Health's Napo Pharmaceuticals Submits Amended Crofelemer Trial Protocol to FDA	MT
17/11	Jaguar Health, Inc., Q3 2025 Earnings Call, Nov 17, 2025
17/11	Gastrointestinal drugmaker Jaguar Health's Q3 net loss narrows	RE
17/11	Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue	PU
15/11	Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
15/11	Jaguar Health : Proxy Statement (dfe8db)	PU
12/11	Jaguar Health, Inc. announced that it expects to receive $10.81 million in funding	CI
10/25/10	Jaguar Health, Inc. announced that it has received $0.999951 million in funding from Brown Stone Capital, LTD	CI
04/25/04	Jaguar Health files for resale of up to 2.6 million shares by selling stockholders - SEC filing	RE
02/25/02	Jaguar Health says on September 28 entered securities purchase agreement with Brown Stone Capital Limited - SEC filing	RE
28/25/28	Jaguar Health, Inc. announced that it expects to receive $0.999951 million in funding from Brown Stone Capital, LTD	CI
26/25/26	Jaguar Health : Corporate Presentation – September 26, 2025 (ba7a24)	PU
24/25/24	Jaguar Health Unit Submits Orphan Drug Status Application to US FDA for Cancer Therapy-Related Diarrhea Drug	MT
10/25/10	Jaguar Health, Inc. announced that it has received $2.380001 million in funding	CI